肯博士的法氏囊.ppt

LohmannAnimalHealthInternationalGainesville,Georgia,USA,Education73-84BSCal.PolyPomona,MSPoultrySc,Auburn,DVM,U.C.Davis,Boardcertified92,KenTakeshita,FosterFarms,CAMgr.HealthServices85-90,ArborAcres,CTDir.PoultryHealth,91-95HealthofUSAPed.,GGP,GP,TechnicalSupportUSA,VinelandLabsDirectorTech.Service;95-01Worldwide,KenTakeshita,HomeofficeVacaville,CAbetweenSac/SF,Mgr.TechnicalServicesWorldwidesupportConcentratedeffortinAmericas,LohmannAnimalHealthInternationalLAHIformedinOctober2000MergerofVineland-MBL-LohmannHeadquarters=GainesvilleGA,LohmannAnimalHealthInternational,EffectiveMay1,2001,TechnicalSupportTeam,Dr.KenTakeshita(USA)Dr.EricLovell(USA)ConsultantDr.DavidShapiro(USA)ConsultantDr.GregCutler(USA)ConsultantDr.CharlesHofacre(USA)ConsultantOpen(USA)Open(LatinAmerica)Dr.HeikeScharr(Germany)Dr.vanDijk(Germany)Dr.CherYew(Singapore)Dr.BeatrizCardoso(Brazil),Dr.KarenBurns(USA),1/1/02,Internationaltripssame;4/yrwhereverneededworldwide,LessintensedomestictravelMorefocusoncustomerfollowuppresentations/techbulletinstrialsandotherprojects,InactivatedIBDVaccines,BursalTissueOrigin(BTO)ChickEmbryoOriginCells(CEO)TissueCultureOrigin(TCO),IBDvirus,bursa,TC(TissueCulture),CEO(ChickEmbryoOrigin),BTO/BD(BursalTissueOrigin)/(BursalDerived),-ChickenEmbryoFibroblast(CEF)-PerpetualcelllinesSignificantvirusadaptationrequired,-Infected,wholechickembryosharvestedSomevirusadaptationrequired,-SPFchickensinfectedbursasharvestedVirusadaptationnotrequired,GrowingtheIBDvirus,BursalTissueOrigin(BTO)orBursalDerived(BD),BTOvaccinesstartedinUKEarly1970s,OriginatedbygroupofUKveterinariansWerenothappywithliveIBDvaccinesaloneProbablychoseBTObecause:EasytogrowGrewtohightiterUKgovernmentrequiredstrictpotencytestsChallengeofchicksfromvaccinatedparentsTheirworkshowedverystrongprotectioninchicksfromvaccinatedparents(to4weeks)VaccineworkwasledbyDr.BoxandproducedbyGlaxo,BTOshowedasbettervaccine,LongerdurationofimmunitywhencomparedtoTCOandCEOvaccinesInUSA,betterabletoprotectagainstvariantIBDstrains,FlocksVaccinatedwithBursalDerivedIBDBetterTiters,FlocksVaccinatedwithBursalDerivedIBDBetterProtection,BTOshowedasbettervaccine,Production:BecauseNOvirusadaptationisrequired,finaloutput“matches”seeds/”matches”challengeViralgrowthVeryhightitersbecausevirusis“home”PotentiallyotherimmunefactorsproducedSocalled“bursin”IncompleteviralparticlesViruscontentwhichis“hidden”fromnormalassay,bursa,TC(TissueCulture),CEO(ChickEmbryoOrigin),BTO/BD(BursalTissueOrigin)/(BursalDerived),AdaptationofIBDvirus,FieldVirus,Significantvirusadaptationrequired,Somevirusadaptationrequired,Novirusadaptationrequired,BTObecamewidelyused,FirstusedinbreedersasonlyIBDvaccineand/oraspartofprogramwithliveprogenyvaccination1stBTOvaccineswere2xcostofTCorCEOvaccinesAstimemovedfrom1970sto1980sUKVi-BursaCE,a“classic”IBDvirus“non”clonedbroadspectrumprobagatedinChickEmbryobroadspectrumintermediateintermediate+invasivenessgoodsafetyingoodprotectioninbroilersandlayersgoodprimerforkilledvaccination,SummaryRecentdevelopmentsVi-BursaCE,“originally”wasVinelandsmostinvasiveIBDbutbecame“mild”“current”serialsaremoreinvasivethanoldserialsprobablyslightlylowerin“invasive”nessthanBursine+.analternativetoBursine/Bursine+?,ViBursaGclassicIBDintermediate=D78tissueculture,ViBursaCEclassicIBDstrongerintermed.likeBursineIIchickembryo,ViBursaLMildcausesminimalimunosuppression,ToBreakThru,LAHI-VinelandLiveIBDVaccines,SummaryRecentdevelopmentsVi-BursaCE,“originally”wasVinelandsmostinvasiveIBDbutbecame“mild”“current”serialsaremoreinvasivethanoldserialsprobablyslightlylowerin“invasive”nessthanBursine+.analternativetoBursine/Bursine+?,Vaccination/challengetrialinprogresstodetermineprotectionagainstvariantvsBursineIIconfirminvasivenessofnewserials,“WordofCaution”,Thinkcarefullybeforesharing“Recentdevelopments”Vi-BursaCEwithendusercanbeanadvantagewithnewcustomeracustomerwhodidnotseeanadvantageusingthe“old”serialsofVi-BursaCEcanbeadisadvantagewithacurrentuserofVi-BursaCE.decideaheadoftime,QuickQuestions.,.orontoPD50,LAHI-VinelandsNDV,PD50,PD50,PD50orViNuChickVac-KspecificallydevelopedforbabychickvaccinationcalledPD50becauseeachdosecontains50protectivedosebychallengetestisa“High”-potencykilledNDV,large#ofprotectioninsmallvolume/dosepotencybyWeybridgeProtectiveDoseTest,PD50,“High”potency=,0.1mldose,50PD50,“High”potency,10PD50,0.5mldose,“Average”potency,vs.,birdsvaccinatedwithdecreasingpartialdoseP(rotective)D(ose)50(%)isdosewhichprotects50%ofbirdschallengedwith“Hot”NDVvirus,PD50,WeybridgeProtectiveDoseTest=,0.1and0.05ml100%protection,0.025ml92%protection,0.0125ml70%protection,0.00612ml30%proteccin,ThisisthePD50pointExtrapolating,onePD50unitofthisvaccineis.0.009ml,CalculationofPD50perdose;-Ifdoseis0.1mlpotencyofvaccineinPD50units=0.1ml/0.009=11-theabovevaccineundertesthasapotencyof11PD50perdose.,ExampleofdeterminingPD50ofavaccine,PD50,0.1mldose,50PD50,PD50,22-25PD50,0.5mldose,“Average”potency,vs.,“Average”killedNDVusedinlayersis=22-25xPD50in0.3-0.5ml,“High”potencyLAHI-VinelandsPD50forchicksis50 xPD50in0.1ml,PD50,Purpose;preventhighlyvelogenicNDVmortalityMethod;SimultaneousliveitsessentialthatkilledNDV=“High”Potency,PD50,Goalof“Simultaneous”live,MiddleEast;reducemortality40%to4%Mexico;simultaneouskilled/liveeffectiveB1live+LAHI-VinelandsPD501dayLaSota7-10days+/-LaSota18dayinhighchallenge,PD50,FieldExperience,PD50,FieldExperience;Serology,NosignificantantibodytiterafterdayoldkilledOnlyhightitersafterchallengehightiter+mortality/clinicalsignspoorprotectionhightiter+nomortality/clinicalsignsgoodprotectionlowtitersnochallenge,PD50,FieldExperience;Serology,PD50,FieldExperience;Serology,Thailand,least0.1ml1dayofagechallengedependent500mlbottle=5,000dosagesinjectIMinlegorSQinneck,P